# A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)

> **NCT02996019** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 180 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Etrolizumab
- **DEVICE:** Auto-Injector (AI)
- **DEVICE:** Prefilled Syringe With Needle Safety Device (PFS-NSD)

## Key facts

- **NCT ID:** NCT02996019
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-07
- **Primary completion:** 2018-04-09
- **Final completion:** 2018-04-09
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2018-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02996019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02996019, "A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02996019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*